These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18779595)

  • 1. Gefitinib maintenance in stage III non-small-cell lung cancer.
    Stewart DJ
    J Clin Oncol; 2008 Oct; 26(29):4849-50; author reply 4850-1. PubMed ID: 18779595
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iressa (gefitinib)].
    Kudoh S; Yoshimura A; Gemma A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gefitinib in non-small cell lung cancer].
    Nakagawa K
    Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
    [No Abstract]   [Full Text] [Related]  

  • 4. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Singh N; Aggarwal AN
    Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
    [No Abstract]   [Full Text] [Related]  

  • 6. Approved use of gefitinib.
    Lyle J
    Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
    Dahlberg SE; Gray RJ; Johnson BE
    J Clin Oncol; 2008 Sep; 26(26):4233-5. PubMed ID: 18779608
    [No Abstract]   [Full Text] [Related]  

  • 8. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 9. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
    William WN; Gold KA; Kim ES
    Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
    Lv P; Zhou T
    Zhongguo Fei Ai Za Zhi; 2010 Mar; 13(3):247-53. PubMed ID: 20673523
    [No Abstract]   [Full Text] [Related]  

  • 11. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
    Kakiuchi S; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 14. Gefitinib does not increase survival in lung cancer patients.
    Golsteyn RM
    Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of clinical response of non-small cell cancer to gefitinib.
    Ardizzoni A; Tiseo M
    JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
    [No Abstract]   [Full Text] [Related]  

  • 16. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 17. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
    Garfield DH
    Lung Cancer; 2006 Nov; 54(2):259. PubMed ID: 16935393
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
    Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U
    Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.